Crohn's Disease Market Enters New Era with Biomarker-Driven and Personalized Treatment Approaches | DelveInsight

(Albany, United States) The Crohn's disease market is predicted to grow substantially in the 7MM. This growth is attributed to several factors, including the increasing prevalence of Crohn's disease, advances in research and development, and innovations in the treatment landscape by various key Crohn's Disease companies such as Celgene, Eli Lilly and Company, Arena Pharmaceuticals, RedHill Biopharma, Janssen, AbbVie, Boehringer Ingelheim, and others.

DelveInsight's report titled "Crohn's Disease Market Insight, Epidemiology, and Market Forecast - 2034" offers a comprehensive analysis of the historical and projected market size for Crohn's disease from 2020 to 2034. The report examines various epidemiology segments and forecasts, explores market trends for Crohn's disease, assesses the competitive landscape, evaluates current and emerging therapeutic approaches, and identifies unmet needs in the treatment of Crohn's disease.

The report notes that the Crohn's Disease market across 7MM is expected to grow substantially over the next ten years from approximately USD 9 billion in 2023. This growth will be driven by the introduction of novel therapies with improved clinical profiles and more convenient routes of administration, a rise in the market penetration of targeted and advanced therapies, advancements in research and development, the identification of new biomarkers for diagnosing Crohn's disease, and an increasing prevalence of the condition.

Download the report to understand which factors are driving the Crohn's disease therapeutic market @ https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

According to the report, the United States accounted for 80% of the total 7MM market share in 2023. Other significant markets, EU4 and the UK, made up approximately 17%, while Japan had the smallest market share at just 3%.

The report provides a comprehensive epidemiological analysis and forecasts extending to 2034. This analysis is segmented by total diagnosed prevalent cases, age-specific cases, severity-specific cases, and treated cases of Crohn's Disease. In 2023, there were approximately 2 million Crohn's Disease diagnosed prevalent cases in the 7MM, and this number is expected to increase during the forecast period. Additionally, age-specific data indicated that the highest prevalence of Crohn's Disease occurred in the age group of 18 to 44 years.

Discover evolving trends in Crohn's disease patient pool forecasts @ https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

The Delveinsight report also discusses current diagnosis and treatment strategies for Crohn's Disease. There is no single test that can definitively confirm a Crohn's disease diagnosis, as its symptoms often resemble those of other conditions, including bacterial infections. A complete assessment, which includes clinical history, physical examination, and various diagnostic tests, is necessary for an accurate diagnosis.

Crohn's disease treatment decisions are guided by factors such as age, comorbidities, symptomatology, inflammation status, the disease location and extent, and the overall risk of developing a more severe or complicated disease. Currently, there is no cure for Crohn's Disease, so it is managed with corticosteroids, immunosuppressive medications, and biologics.

Some of the drugs approved for the management of Crohn's Disease include NTYVIO (Takeda Pharmaceutical), STELARA (Janssen Pharmaceuticals), CIMZIA (UCB), TYSABRI (Biogen), REMICADE (Janssen Biotech), HUMIRA (AbbVie), ALOFISEL (Takeda Pharmaceuticals), Budesonide (AstraZeneca/Tillotts Pharma), SKYRIZI (AbbVie and Boehringer Ingelheim), and RINVOQ (AbbVie).

Recently, in January 2025, OMVOH (Eli Lilly and Company) was approved by the FDA for treating moderately to severely active Crohn's disease in adults. According to DelveInsight's Crohn's Disease Market Report, Adalimumab captured the highest market share for Crohn's Disease in 2023, with USD 3 billion across the 7MM.

Unlock which emerging Crohn's disease drug is expected to capture the largest market share in 7MM by 2034: https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Despite significant advancements in treatment, existing therapies are associated with various challenges, such as side effects due to long-term use, high costs, patient adherence issues, healthcare burdens, and additional costs linked to complications from comorbidities. These factors highlight the urgent need for improved therapies for Crohn's Disease.

DelveInsight's analysis indicates that the current developmental pipeline for Crohn's Disease treatments is robust, with several companies initiating clinical trials for new options. The pipeline includes drugs such as Mirikizumab (Eli Lilly and Company), RHB-104 (edHill Biopharma), ZEPOSIA (Celgene), VELSIPITY (Arena Pharmaceuticals), TREMFYA (Johnson and Johnson), RYONCIL (Mesoblast), MT-1303 (Mitsubishi Tanabe Pharma Corporation), PRA023 (Prometheus Biosciences/Merck), AVB-114 (Avobis Bio LLC), ABX464 (Abivax S.A), and RVT-3101/PF-06480605 (Pfizer), among others.

In February 2025, the FDA granted Fast Track designation to AVB-114 (Avobis Bio LLC) for the treatment of Crohn's perianal fistulas. These recent developments indicate positive momentum in the field.

Although Crohn's disease poses significant challenges, such as the rise of biosimilars, delays in accurate diagnosis, and complications in treating patients with difficult-to-manage fistulas, the introduction of new therapies is expected to drive market growth.

Table of Contents
1. Key Insights
2. Report Introduction
3. Crohn's Disease Market Overview at a Glance
4. Executive Summary of Crohn's Disease
5. Key Events
6. Crohn's Disease Background and Overview
7. Methodology
8. Crohn's Disease Epidemiology and Patient Population
9. Crohn's Disease Patient Journey
10. Crohn's Disease Marketed Therapies
11. Crohn's Disease Emerging Therapies
12. Crohn's Disease: Seven Major Market Analysis
13. KOL Views
14. SWOT Analysis
15. Crohn's Disease Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

Related Reports
Crohn's Disease Pipeline Insight
https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Crohn's Disease Pipeline Insight provides comprehensive insights about the Crohn's Disease pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Crohn's Disease companies, including Anssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, and Bristol-Myers Squibb among others.

Contact Us:
Arpit Anand
info@delveinsight.com
+14699457679

About DelveInsight:
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.

This release was published on openPR.